Microsphere as a novel strategy for the long-term use of corticosteroids in asthma patients during the COVID-19 Pandemic
1 Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
2 Department of Biomedical Sciences, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Review Article
World Journal of Advanced Research and Reviews, 2022, 13(01), 468–472
Article DOI: 10.30574/wjarr.2022.13.1.0020
Publication history:
Received on 06 December 2021; revised on 10 January 2022; accepted on 12 January 2022
Abstract:
The use of corticosteroids during the (Coronavirus Disease 2019) COVID-19 has become a new concern. Corticosteroids are the main therapy in asthmatic patients with anti-inflammatory and immunosuppressant effects. Patients with the need for long-term use of corticosteroids, such as asthma patients, are aware of the risk from infection obtained by the side effect of long-term corticosteroid use. A Recent study has innovated a new drug delivery agent, called Microsphere that can specify the targeted therapy. This new therapy may potentially increase the treatment efficacy with the lesser side effects. Here we review a study that uses the Microsphere for delivering corticosteroids. Additional studies are warranted to support the use of Microspheres as novel drug delivery for asthma patients during the COVID-19 pandemic.
Keywords:
Asthma; Corticosteroids; COVID-19; Microsphere; Therapy
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0